Alpha Bioventure
Bispecific antibody development technology platform and anti-cancer antibody drugs
Alpha Bioventure has launched a bispecific antibody technology platform in Princeton, New Jersey, trying to promote the clinical development of antibody drugs. We cooperate with entrepreneurs who have successful entrepreneurial experience in anti-cancer drugs discovery.
A project for nasal diseases founded in Pennsylvania is now in stable progress. We make use of nasal immunization technology to accelerate the discovery process of nasal medicine.
Alpha Bioventure has invested the IVIEW Therapeutics, which developed proprietary PVP-I based sustained release products platform to produce in-situ gel formulations resulting in a long lasting and less toxic pharmacological effect in the eye and the nasal cavity.
Alpha Bioventure is recruiting fund projects, and you can see details through our Join Us page.
Email:
We welcome any feedback and will respond to your questions, suggestions or comments wherever possible.